Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 219, Issue 1, Pages 26-30Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiy466
Keywords
Guillain-Barre syndrome; neutralizing antibody; flavivirus; Zika; dengue
Categories
Funding
- NIH National Center for Advancing Translational Sciences [UL1TR001876, KL2TR001877]
- National Institute of Allergy and Infectious Diseases, NIH [P01AI106695]
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001876, KL2TR001877] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI106695] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The role of neutralizing antibodies in Zika-induced Guillain-Barre syndrome (GBS) has not yet been investigated. We conducted a case-control study using sera from the 2016 Zika epidemic in Colombia to determine the neutralizing antibody activity against Zika virus (ZIKV) and dengue virus serotype 2 (DENV2). We observed increased neutralizing antibody titers against DENV2 in ZIKV-infected individuals compared with uninfected controls and higher titers to both ZIKV and DENV2 in ZIKV-infected patients diagnosed with GBS compared with non-GBS ZIKV-infected controls. These data suggest that high neutralizing antibody titers to DENV and to ZIKV are associated with GBS during ZIKV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available